Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery
NCT00697099
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
2326
Enrollment
INDUSTRY
Sponsor class
Conditions
Venous Thromboembolism
Interventions
DRUG:
Semuloparin sodium
DRUG:
Enoxaparin sodium
DRUG:
Placebo
Sponsor
Sanofi